RFA-CA-22-022: Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
Closed
This grant is closed. A newer notice from the same program is open now: Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) (RFA-CA-27-019). Status: Closes October 19, 2027 (346 days left). It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 17, 2022.
From the official notice on Grants.gov, last changed March 24, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsOptional
- Funded byNCI
- Median yearly award$397,241
- Typical project length4 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-CA-22-022 were run by National Cancer Institute (NCI, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-22-022 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-CA-27-019 | May 21, 2026 | Closes October 19, 2027 (346 days left) | Open |
| RFA-CA-24-017 | December 14, 2023 | Closed November 15, 2024 | Closed |
| RFA-CA-23-015 | December 22, 2022 | Closed November 17, 2023 | Closed |
Key dates
| Posted | March 24, 2022 |
|---|---|
| Deadline | November 17, 2022 |
| Archived by Grants.gov | December 23, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the money in the 5 programs behind this notice (61% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The goal of this FOA is to advance cancer model systems that recapitulate human immunity in the tumor microenvironment to improve the predictivity of immuno-oncology studies. Proposed research projects must focus on recapitulation of the human immune system in their proposed cancer model using human cells or tissues to regenerate and/or recapitulate the human immune system in in vivo or in vitro immuno-oncology models in a manner that matches or exceeds representation of the human immune system achieved with murine models developed using HFT. Models derived from genetically manipulated immune systems without introduction of human immune lineage cells will not be considered responsive. The FOA will utilize the R33 Exploratory/Developmental Grants Phase II research activity code.
Funded under RFA-CA-22-022 so far
NIH funded 6 projects under RFA-CA-22-022 in fiscal 2023 to 2025, at 6 institutions. The median yearly award was $397,241.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| m6A-suite: an informatics pipeline and resource for elucidating roles of m6A epitranscriptome in cancer | University of Pittsburgh at Pittsburgh | 2025 | $207,510 |
| Inferring Kinase Activity from Tumor Phosphoproteomic Data | University of Virginia | 2025 | $186,447 |
| Visual Analytics for Exploration and Hypothesis Generation Using Highly MultiplexedSpatial Data of Tissues and Tumors | Harvard Medical School | 2025 | $416,968 |
| Robust privacy preserving distributed analysis platform for cancer research: addressing biased, incomplete data | University of Pennsylvania | 2025 | $397,241 |
| Personalization of graphical models using multi-omics data for subtype discovery and prognosis | Auburn University at Auburn | 2025 | $1,460 |
| Matching genotypes with personalized therapies: Development of a decision support infrastructure to augment the value of precision medicine | Johns Hopkins University | 2025 | $407,737 |
Who has won Cancer Treatment Research grants before
From fiscal 2021 to 2025, Cancer Treatment Research (93.395) awarded $5.6 billion across 3,622 grant awards, an average of $1.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 144 | $188 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 68 | $185 million |
| Icahn School of Medicine at Mount Sinai | New York | 35 | $179 million |
| Public Health Institute | California | 4 | $168 million |
| Fred Hutchinson Cancer Center | Washington | 57 | $156 million |
Who has won Cancer Biology Research grants before
From fiscal 2021 to 2025, Cancer Biology Research (93.396) awarded $4.3 billion across 3,142 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 70 | $151 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 109 | $144 million |
| Sloan-Kettering Institute for Cancer Research | New York | 66 | $136 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 47 | $107 million |
| The Regents of the University of California, San Francisco | California | 64 | $95.5 million |
Who has won Cancer Cause and Prevention Research grants before
From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 81 | $107 million |
| Sloan-Kettering Institute for Cancer Research | New York | 65 | $99.1 million |
| The Trustees of Columbia University in the City of New York | New York | 48 | $85.3 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 51 | $83.1 million |
| University of North Carolina at Chapel Hill | North Carolina | 49 | $76.1 million |
Other programs behind this notice
Applying now
This notice no longer takes applications. Apply under the newer notice, RFA-CA-27-019, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-22-022 still open?
No. It closed on November 17, 2022. A newer notice is open: RFA-CA-27-019, closes October 19, 2027 (346 days left).
Who can apply for Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)?
Closed November 17, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-CA-22-022?
NIH RePORTER lists 6 projects funded under RFA-CA-22-022 in fiscal 2023 to 2025, at 6 institutions. The most were at University of Pittsburgh at Pittsburgh, University of Virginia, Harvard Medical School.
Who has won Cancer Cause and Prevention Research grants before?
The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)